Anticoagulant therapy control in primary healthcare setting
Abstract
The aim of the study was to evaluate efficiency anticoagulant therapy control in primary healthcare setting. The prospective, controlled study involved 301 patients with «non-valvular» atrial fibrillation, receiving various anticoagulant drugs in 2013–2015. After discharge the patients were advised to visit anticoagulant therapy control department. The risk of thromboembolic complications and the risk of bleeding were assessed with CHA2DS2VASc scale HAS-BLED, respectively. Major bleeding was assessed with TIMI scale. The time in therapeutic range for Warfarin was assessed for the patient taking warfarin. The study involved 301 patients with non-valvular atrial fibrillation taking anticoagulants: warfarin – 49 (16%), rivaroxaban – 34 (11%), apixaban – 81 (28%) and dabigatran –137 (45%). Minor bleeding was found in all groups. Large bleeding was found in patients receiving warfarin, dabigatran and rivaroxaban.
About the Authors
Z. K. Salpagarova
I.M. Sechenov First MSMU
Russian Federation
Russian Federation
Zukhra K. Salpagarova - Postgraduate Student at the Department of Preventive and Urgent Cardiology, I.M. Sechenov First MSMU.
8/2, Trubetckaya str., Moscow, 119991
Tel.: +7 (499) 248-73-89, +7 (928) 382-99-99
D. A. Andreev
I.M. Sechenov First MSMU
Russian Federation
Russian Federation
Doctor of Medical Science, Professor with the Department of Preventive and Urgent Cardiology, I.M. Sechenov First MSMU
8/2, Trubetckaya str., Moscow, 119991
D. A. Sichev
Russian Medical Academy of Post-Graduate Education
Russian Federation
Russian Federation
Head of the Department of Clinical Pharmacology and Therapy, Russian Medical Academy of Post-Graduate Education.
A. A. Bikova
I.M. Sechenov First MSMU
Russian Federation
Russian Federation
Assistant Professor with the Department of Preventive and Urgent Cardiology, I.M. Sechenov First MSMU.
8/2, Trubetckaya str., Moscow, 119991
S. A. Syrkin
I.M. Sechenov First MSMU
Russian Federation
Russian Federation
Doctor of Medical Science, Professor, Head of the Department of Preventive and Urgent Cardiology, I.M. Sechenov First MSMU.
8/2, Trubetckaya str., Moscow, 119991
S. A. Suchkova
I.M. Sechenov First MSMU
Russian Federation
Russian Federation
Postgraduate Student at the Department of Preventive and Urgent Cardiology, I.M. Sechenov First MSMU.
8/2, Trubetckaya str., Moscow, 119991
References
1. Goldhaber S.Z., Bounameaux H. Pulmonary embolism and deep vein thrombosis. Lancet. 2012; 379: 1835–1846.
2. Mani H., Lindhoff-Last E. New oral anticoagulants in patients with nonvalvular atrial fibrillation: a review of pharmacokinetics, safety, efficacy, quality of life, and cost effectiveness. Drug Des. Devel. Ther. 2014; 8: 789–798.
3. Ansell J., Hirsh J., Hylek E. et al. Pharmacology and management of the vitamin K antagonists: American college of chest physicians evidence-based clinical practice guidelines (8th ed.). Chest. 2008; 12 (6): 160–198.
4. Wan Y., Heneghan C., Perera R. et al. Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review. Circ. Cardiovasc Qual Outcomes. 12 (2): 84–91.
5. Calvo Romero J.M., Lima Rodriguez E.M. New oral anticoagulants in the treatment of venous thromboembolic disease. Semergen. 2013; 39 (3): 146–149.
6. Healey J.S., Eikelboom J., Douketis J. et al. Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. Circulation. 2012; 126 (3): 343–348.
Review
Views:
260
Email this article 